Managing Treatment for ALK Rearranged Lung Cancer

This chapter examines the critical safety considerations and treatment strategies for patients undergoing lorlatinib therapy for metastatic non-small cell lung cancer with an ALK rearrangement. It emphasizes the need for careful monitoring of neurocognitive effects, genetic testing, and psychiatric history, particularly for older patients and those with comorbidities. The discussion also explores the complexities of treatment efficacy, tolerability, and the balance between addressing patient-specific risks and therapeutic benefits.